文献速递慢性肾脏病

计算与实测白蛋白肌酐比值对慢性肾脏病患者肾衰竭和死亡的预测

Calculated versus measured albumin-creatinine ratio to predict kidney failure and death in people with chronic kidney disease.
PubMed 文献 · Kidney Int · 2022-04-07

研究基于加拿大阿尔伯塔省人群数据,纳入中重度慢性肾脏病成人,比较计算(基于尿试纸蛋白或蛋白肌酐比值PCR)与实测白蛋白肌酐比值(ACR)预测肾衰竭和无肾衰竭死亡的模型表现。结果显示PCR计算ACR与实测ACR预测一致性优于试纸计算ACR,试纸计算ACR校准逐年变差,但判别力相似;若在不同种族中验证,计算ACR可用于无法获得实测ACR时的风险预测,PCR计算ACR可能优于试纸计算ACR。

要点

  • 基于PCR计算的白蛋白肌酐比值预测表现可能优于基于尿试纸计算者。
  • 计算与实测白蛋白肌酐比值的预测模型判别力相似。
  • 试纸计算的白蛋白肌酐比值从第3年起校准变差。

核心结论

  • 若在不同种族人群中得到验证,计算白蛋白肌酐比值可在无法获得实测值时用于风险预测。
  • 基于PCR计算的白蛋白肌酐比值预测表现可能优于基于试纸计算者。

研究设计与样本

  • 基于加拿大阿尔伯塔省人群数据,纳入2008年4月1日至2017年3月31日期间成年中重度慢性肾脏病患者,随访至2019年3月31日。
  • 训练队列包括ACR-试纸队列18731人和ACR-PCR队列4542人,测试队列分别821人和1831人,测试采用加拿大曼尼托巴省同一算法创建的队列。
  • 训练竞争风险模型预测肾衰竭和无肾衰竭死亡,模型纳入年龄、性别、估算肾小球滤过率、糖尿病、心血管疾病及实测或计算的白蛋白肌酐比值。

主要发现

  • 内部和外部测试中,基于实测与基于PCR计算的白蛋白肌酐比值的预测一致性高于基于实测与基于试纸计算者。
  • 试纸计算的白蛋白肌酐比值在两种结局中从第3年起Brier评分高于实测值,提示校准变差。
  • 包含实测或计算白蛋白肌酐比值的模型判别力相似:第1至5年肾衰竭的受试者工作特征曲线下面积为83-89%,死亡为69-75%。

临床怎么用

  • 作者认为,若在不同种族人群中得到验证,计算白蛋白肌酐比值可在无法获得实测值时用于风险预测。
  • 作者指出,基于PCR计算的白蛋白肌酐比值预测表现可能优于基于试纸计算者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Albumin-to-creatinine ratio (ACR), the preferred method to quantify proteinuria, can be calculated from urine dipstick protein or protein-to-creatinine ratio (PCR). The performance of calculated vs. measured ACR in predicting kidney failure and death without kidney failure in people with chronic kidney disease (CKD) is unknown. Here, we used population-based data from Alberta, Canada, to identify adults with incident moderate-severe CKD (sustained for more than 90 days) from 2008-04-01 to 2017-03-31, who had same-day measures of ACR and urine dipstick (ACR-dipstick cohort) or PCR (ACR-PCR cohort) in the two years before cohort entry. We followed participants until 2019-03-31 and trained competing risk models of kidney failure and death without kidney failure including age, sex, estimated glomerular filtration rate, diabetes, cardiovascular disease, and either measured or calculated ACR. Model performance was tested in cohorts created using the same algorithm in Manitoba, Canada. The ACR-dipstick and ACR-PCR cohorts included 18,731 and 4,542 people (training cohorts) and 821 and 1,831 people (testing cohorts), respectively. In internal and external testing, there was closer agreement between predictions based on measured vs. PCR-calculated ACR than between those based on measured vs. dipstick-calculated ACR. The dipstick-calculated ACR had higher Brier scores than measured ACR from year three for both outcomes, indicating worsening calibration. Models including measured or calculated ACR had similar discrimination: year one-to-five area under the receiver operating characteristic curve of 83-89% for kidney failure and 69-75% for mortality. Thus, if confirmed in different ethnic groups, calculated ACR can be used for risk predictions when the measured ACR is not available. PCR-calculated ACR may have superior performance to dipstick-calculated ACR.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Al-Wahsh H, Lam NN, Quinn RR, et al. Calculated versus measured albumin-creatinine ratio to predict kidney failure and death in people with chronic kidney disease. Kidney Int. 2022. PMID: 35398476. doi:10.1016/j.kint.2022.02.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。